Incyte Corporation (INCY)
Dopo ore:
| Chiusura precedente | 75,97 |
| Aperto | 75,58 |
| Denaro | 77,70 x 1100 |
| Lettera | 77,64 x 1200 |
| Min-Max giorno | 75,38 - 77,86 |
| Intervallo di 52 settimane | 61,91 - 84,86 |
| Volume | |
| Media Volume | 1.442.532 |
| Capitalizzazione | 17,204B |
| Beta (5 anni mensile) | 0,71 |
| Rapporto PE (ttm) | 18,10 |
| EPS (ttm) | 4,29 |
| Prossima data utili | 01 ago 2022 - 05 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 91,86 |
- GlobeNewswire
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitorsCHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel fo
- GlobeNewswire
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a rang
- GlobeNewswire
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreeme
